Sigma receptor (R) antagonists attenuate many behavioral effects of cocaine but typically not its reinforcing effects in selfadministration procedures. However, the R antagonist rimcazole and its N-propylphenyl analogs, [3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]diphenylamine hydrochloride (SH 3-24) and 9-[3-(cis-3,5-dimethyl-4-[3-phenylpropyl]-1-piperazinyl)-propyl]carbazole hydrobromide (SH 3-28), dosedependently decreased the maximal rates of cocaine selfadministration without affecting comparable responding maintained by food reinforcement. In contrast, a variety of (BD 1063), and N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine monohydrochloride (NE-100)] had no effect on cocaine self-administration across the range of doses that decreased rates of food-maintained responding. Rimcazole analogs differed from selective R antagonists in their dual affinities for Rs and the dopamine transporter (DAT) assessed with radioligand binding. Selective DAT inhibitors and R antagonists were studied alone and in combination on cocaine self-administration to determine whether actions at both Rs and the DAT were sufficient to reproduce the effects of rimcazole analogs. Typical DAT inhibitors [2-carbomethoxy-3-(4-fluorophenyl)tropane (WIN 35,428), methylphenidate, and nomifensine] dose-dependently shifted the cocaine dose-effect curve leftward. Combinations of DAT inhibitor and R antagonist doses that were behaviorally inactive alone decreased cocaine self-administration without effects on food-maintained responding. In addition, whereas the DAT inhibitors were self-administered at rates similar to those of cocaine, neither rimcazole analogs nor typical R antagonists (NE-100 and AC927) maintained responding above control levels across a wide range of doses. These findings suggest that the unique effects of rimcazole analogs are due to dual actions at the DAT and Rs and that a combined target approach may have utility in development of medical treatments for cocaine abuse.